Market price analysis of single box of Futibatinib

Futibatinib (Futibatinib), as an innovative targeted drug for intrahepatic cholangiocarcinoma (iCCA) , has not yet been marketed in China, and therefore is not included in the reimbursement scope of China's medical insurance. If patients need to use it, they usually rely on overseas purchases or international pharmacy channels. The Japanese version of the original drug forbatinib has been launched in overseas markets, with a specification of 4 mg × 35 tablets, and the price per box is about 30,000 yuan. The price reflects the research and development costs of the originator drug, its scarcity, and its precisely targeted nature against rare, advanced cancers.

In order to reduce the financial burden on patients, some countries and regions have launched generic versions of drugs. For example, the Laos version of the generic version of forbatinib has been launched. The drug ingredients are basically the same as the original drug and the clinical effects are similar, but the price has dropped significantly to about 2,500 yuan per box. The emergence of generic drugs provides affordable options for patients requiring long-term treatment or maintenance therapy while increasing access to medicines.

In terms of purchase channels, overseas drugs must be obtained through regular international pharmacies, cross-border medical institutions or imported drug service platforms with registration qualifications. Patients should pay attention to choosing regular drugs with batch numbers, complete packaging and English instructions to ensure efficacy and safety. Since forbatinib is a prescription drug, it must be evaluated by a doctor before use to ensure that the patient carries FGFR2 gene fusion or rearrangement and meets the indication requirements.

Judging from price trends, the high market value of original drugs is mainly affected by research and development costs, global supply and patent protection, while the emergence of generic drugs is expected to further reduce costs in the future. For domestic patients, as cross-border drug purchase channels mature and rare disease drug approval policies are relaxed, it is expected that forbatinib will be more likely to be launched in China and entered into the medical insurance directory, which will significantly improve patient accessibility and the sustainability of long-term treatment.

Reference materials:https://www.lytgobi.com/